Abstract:Polo-like kinase 1 (Plk1) belongs to a subfamily of Ser/ Thr protein kinases, collectively termed polo-like kinases (Plks). A growing body of evidence suggests that Plk1 plays important roles during multiple stages of M-phase progression and, as a result, in cell proliferation. In a series of preclinical studies, PLK1 has been validated as a cancer target. This has prompted many research scientists to develop selective PLK1 inhibitors for the treatment of cancer. The recent strategy employed in PLK1 inhibition involves the designing of small molecule inhibitors that targets the classical ATP-binding site of PLK1. Purpurogallin (PPG) and poloxin have been reported as inhibitors of the polo-box domain (PBD) of human polo-like kinase 1. Recently, new generation of PLK1 inhibitors targeting the second druggable domain of PLK1, the polo box domain, is currently being tested preclinically. We propose to design and develop 1, 3-thiazolidin-4-ones which could inhibit PLK1 for potent anticancer and anti-inflammatory activities. The 1, 3-thiazolidin – 4-ones could show anticancer and anti-inflammatory potential through inhibition of polo-like kinase 1 (PLK1) and cyclooxygenase-2 (COX 2) via NF-Kb (nuclear factor kappa-light- chain-enhancer of activated B cells) protein. Molecular docking of a set of ligands was performed using Vlife MDS 4.4 software. The 3D ligand protein complex structure of Polo Like Kinase 1 (2rku) was obtained from the protein database bank (RCSB-PDB) and processed for protein preparation and optimization. The computational studies suggest that aromatic group with non-polar electronegative substituents at second position and nitro-heterocycle either directly or through amide linkage at third position of the 1, 3-thiazolidin – 4-ones could result in better anticancer compound through inhibition of enzyme polo-like kinase 1.

Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.

Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1

Identification of A Novel Polo-Like Kinase 1 Inhibitor That Specifically Blocks the Functions of Polo-Box Domain

Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.

Developments of Polo-like Kinase 1 (plk1) Inhibitors As Anti-Cancer Agents

Dynamic and Multi-Pharmacophore Modeling for Designing Polo-Box Domain Inhibitors

Identification of Novel Polo-Like Kinase 1 Inhibitors by a Hybrid Virtual Screening.

Kinase Domain Inhibitors of PLK1: SAR and Interaction Mode

Identification of indole-3-carboxylic acids as non-ATP-competitive Polo-like kinase 1 (Plk1) inhibitors.

Leveraging the Fragment Molecular Orbital Method to Explore the PLK1 Kinase Binding Site and Polo-Box Domain for Potent Small-Molecule Drug Design

Identification of Nitroimidazole-Oxime Derivatives Targeting the Polo-Box Domain of Polo-Like Kinase 1.

Exploring Novel PLK1 Inhibitors Based on Computational Studies of 2,4-Diarylaminopyrimidine Derivatives

Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors

Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential

Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of PLK1

Advance of Ser/Thr Kinase Polo-like Kinase 1(Plk1) Research

Molecular Docking Studies of 1, 3- Thiazolidin-4-Ones as Potential Human Polo Like Kinase 1 (Plk 1) Inhibitors

Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1

Pharmacological and Functional Comparison of the Polo-like Kinase Family: Insight into Inhibitor and Substrate Specificity

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor